Nexium Control 28 Tablet Pack

Nexium Control 28 Tablet Pack shot

Improved value & convenience for patients with recurrent frequent heartburn

Exclusive to pharmacy, the new Nexium Control pack size, 28 tablets, offers benefits for patients who have used esomeprazole with positive results:

  • Improved value at a lower cost per tablet
  • Product available on hand for future episodes
  • Meets the shopper needs for larger packs1

Access educational resources to support the recommendation of Nexium 28 tablet pack.

Flowchart of frequent and occasional heartburn

How to recommend the 28 tablet pack size for Nexium Control

  • One tablet per day
  • Maximum 14 consecutive days use
  • If symptoms do not resolve or get worse after 14 days refer to a GP
  • *Should symptoms recur after 3 months, patients may restart a further treatment course. If less than three months after previous treatment, it is advisory to refer patients to seek advice from a GP2

Read more

Understanding frequency is key to an appropriate recommendation

  • Ask patients how often they suffer – more than once a week is classed as frequent heartburn
  • Patients with frequent heartburn may benefit from a PPI such as Nexium Control to give the oesophagus a ‘holiday’ from acid and reduce sensitivity

Learn more about the role of frequency in heartburn treatment recommendations.

Recommend Nexium Control to patients with heartburn more than once per week

Nexium Control 28 tablet pack

Nexium Control 28 tablet pack

For patients with recurrent frequent heartburn who have used esomeprazole successfully and seek the value and convenience of a larger pack.

Nexium Control 7 and 14 tablet packs

Nexium Control 7 and 14 tablet packs

Nexium Control 7 tablet pack is an ideal trial pack with one-week supply. Nexium Control 14 tablet pack offers the same protection and offers a 2-week treatment course.

Nexium Control 14 Capsule pack

Nexium Control 14 Capsule pack

Easy-to swallow mini capsules – 53% smaller than tablet* in a portable bottle. Complete 14-day treatment course.

*based on volume

Nexium Control Product Information

  • Product Information

    Nexium Control 20 mg gastro-resistant tablets and Nexium Control 20 mg gastro-resistant hard capsules (Esomeprazole). Indications: The short-term treatment of reflux symptoms (e.g., heartburn and acid regurgitation) in adults. Dosage: The recommended dose is 20 mg (one tablet or capsule) per day. Tablets or capsules may need to be taken for 2-3 consecutive days to achieve symptom improvement. Maximum treatment duration: up to 2 weeks. Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients. Esomeprazole must not be used concomitantly with nelfinavir. Warnings and precautions: Patients should consult a doctor if: They have significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded to avoid delay in diagnosis. Also, if they have had previous gastric ulcer or gastrointestinal surgery, been on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks, have jaundice or severe liver disease, are aged over 55 years with new or recently changed symptoms. Long-term recurrent symptoms of indigestion or heartburn require regular doctor consultation and those over 55 years taking any non-prescription indigestion or heartburn remedy daily should inform their pharmacist or doctor. Nexium Control should not be taken as a long-term preventive product. Treatment with PPIs may lead to a slightly increased risk of GI infections such as Salmonella and Campylobacter and in hospitalised patients, possibly Clostridium difficile. Patients should consult their doctor before taking this medicinal product if they are due to have an endoscopy or urea breath test. Co-administration of esomeprazole with atazanavir is not recommended. The potential for interactions with medicinal products metabolised through CYP2C19 should be considered. Concomitant use with clopidogrel is discouraged. Not to be taken with another PPI or H2 antagonist. Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. PPIs are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE). If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, medical help should be sought promptly, and discontinuation considered. SCLE after previous treatment with a PPI may increase the risk of SCLE with other PPIs. Contains sugar spheres (sucrose). Not suitable for patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency. Side effects: Refer to the SPC for full details. Common: headache and GI disorders, including abdominal pain, constipation, diarrhoea, and nausea/vomiting, fundic gland polyps (benign). Uncommon: peripheral oedema, insomnia, dizziness, paraesthesia, somnolence, vertigo, dry mouth, increased liver enzymes, dermatitis, pruritus, rash and urticaria. Legal category: GSL (7s and 14s) and P (28s). Product licence number: GSL: Capsules PLGB 44673/0221 & Tablets PLGB 44673/0222, P: Tablets PLGB 44673/0225. MAH: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, U.K. RRP (excl VAT): Tablets: 7s £5.99, 14s £10.39, 28s £17.59. Capsules: 14s £11.19. Text prepared: Aug 2023

Nexium Control – UK’s No 1 24 hour heartburn protection3

Icon of stomach

Overview of frequent heartburn

Find out more about frequent heartburn including a profile of a patient who may suffer from the condition.

Find out more

Man watching webinar

Webinars & Events

Register now to access a range of webinars and education modules online.

Register now

Book icon

Educational resources

Access educational resources to support your team’s understanding of heartburn and its management.

Find out more